Besides, TFEB could elevate PD-L1 expressions to promote immune evasion resistance to mTOR inhibition in renal cell carcinoma, highlighting the significant relationships between TFEB and immunotherapy [49]. The gene discussed is MTOR; the disease is hereditary clear cell renal cell carcinoma.